"FDA set to approve groundbreaking Alzheimer's drug, but concerns remain for diverse patient populations"

The U.S. Food and Drug Administration (FDA) is expected to grant full approval to Leqembi, a drug designed to slow the progression of Alzheimer's disease. Clinical trials have shown that Leqembi can slow cognitive decline by 27% in early-stage Alzheimer's patients. If approved, Leqembi would be the first drug to receive full FDA approval for slowing the progress of Alzheimer's. The drug works by targeting and breaking down specific proteins associated with the disease. Leqembi is estimated to cost around $25,000 per year for treatment. Another drug, Aduhelm, has received conditional approval but lacks proven benefits.